Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
GRI Bio Inc
GRI
Healthcare
Biotechnology
GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in...
the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). Its product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. The Company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) or lupus and multiple sclerosis (MS).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:GRI)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 14, 2024 4:20pm
New Press Release - GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker studyTopline data of GRI-0621 readout expected in Q2 2025Currently available treatments for IPF are limited with...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 24, 2024 8:30am
New Press Release - GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)Current treatment options for IPF are limited with only 2...
read article.
Redefining Neuroprotection: Revive’s Approach to Treating Brain Injury from Nerve Agents
posted Dec 03, 2024 9:00am by
Revive Therapeutics Ltd
-
|
Evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. ...read more
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 21, 2024 5:36pm
New Press Release - GRI Bio Announces Exercise of Warrants
LA JOLLA, CA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it...
read article.
(72)
•••
Iseneschal
X
Comment by
Iseneschal
on Oct 21, 2024 9:50am
RE:GRI....Halt #2
Nice Short scalp ....not as much as I thought but going to be able to buy a huge Strip loin slab of beef for over $300 bucks Roar !!!!!!!!!!!!!!!!!
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 21, 2024 9:45am
GRI....Halt #2
Going to cover my short position ; ) Minimum....Fiddy cent profit /sh Cheers !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 21, 2024 8:28am
GRI....on 2nd thought
Short set up here...picking my spot ; ) Cheers !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 21, 2024 8:27am
GRI.....missed this one for sure
Not chasing it now...currently at $1.70
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 16, 2024 3:33pm
GRI....is everyone ready for the "rug pull" ????
No position Scalped this 2 x's today
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 16, 2024 1:25pm
GRI.....I'd say this is done for the day...
Reason....ST Pumper jumped on board That is the "Kiss o Death"
(72)
•••
Iseneschal
X
Comment by
Iseneschal
on Oct 16, 2024 1:03pm
RE:GRI....LoL....crash Boom Bang
Probably get another run before the close ; ) Me no position I like leaving some for the next guy. Cheers !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 16, 2024 12:53pm
GRI....LoL....crash Boom Bang
Drpped like a rock right after I sold Cheers !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 16, 2024 12:45pm
GRI.....Sold all into the H.O.D
Cheers ....Thanks Mr. M Excellent trade !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 16, 2024 8:49am
GRI...early a.m runner on NR....I'm in ; )
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in
...more
(271)
•••
whytestocks
X
Post by
whytestocks
on Sep 26, 2024 1:31pm
GRI Bio Receives Authorization to Conduct Phase 2a Biomarker
Breaking News: $GRI GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in AustraliaMHRA and HREC authorization in Australia further expands and will potentially
...more
(0)
•••
Tlkuuu
X
Post by
Tlkuuu
on Feb 03, 2024 6:42pm
GRI going to rise to 8-10 next week. the price now is no goo
It's the best buy .
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages